Verrica Pharmaceuticals
Presença
Verrica Pharmaceuticals é uma empresa listada sob o símbolo VRCA (US).
Executivos
Veja o organograma con seus 14 executivos principais
Biografias mais buscadas da Verrica Pharmaceuticals
- Ted White, Director, President and Chief Executive Officer
- Lawrence Eichenfield, Director
- Sean Stalfort, Director
Criar um alerta
para seguir os movimentos de executivos da Verrica Pharmaceuticals.
Farmacêutica
Verrica Pharmaceuticals possui 1.863 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™ - Verrica Pharmaceuticals
- View more press releases Close
Redes sociais sobre Verrica Pharmaceuticals
- Verrica Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Verrica Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Ted White 
Ligue para a Verrica Pharmaceuticals em +1 484...
